Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 13/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.37 |
| ▸ | RELA | Q04206 | 1/20 | 0.37 |
| ▸ | CTSL | P07711 | 2/20 | 0.36 |
| ▸ | CTSS | P25774 | 2/20 | 0.36 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.34 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3935052 | 0.93 | SMN1; SMN2 (0.44) | SMN1; SMN2CTSKNFKB1NFKB2RELA | |
| SCHEMBL7541004 | 0.84 | SMN1; SMN2 (0.48) | SMN1; SMN2CTSKNFKB1NFKB2RELA | |
| SCHEMBL28659964 | 0.84 | SMN1; SMN2 (0.48) | SMN1; SMN2CTSKNFKB1NFKB2RELA | |
| SCHEMBL3194820 | 0.83 | CTSK (0.43) | SMN1; SMN2CTSKNFKB1NFKB2RELA | |
| SCHEMBL3194826 | 0.83 | CTSK (0.43) | SMN1; SMN2CTSKNFKB1NFKB2RELA | |
| SCHEMBL3935163 | 0.82 | SMN1; SMN2 (0.42) | SMN1; SMN2CTSKCTSLCTSSCTSB | |
| SCHEMBL2245259 | 0.82 | SMN1; SMN2 (0.47) | SMN1; SMN2CTSKCTSLCTSSCTSB | |
| SCHEMBL2239241 | 0.82 | SMN1; SMN2 (0.47) | SMN1; SMN2CTSKCTSLCTSSCTSB | |
| SCHEMBL1645916 | 0.81 | SMN1; SMN2 (0.45) | SMN1; SMN2CTSKCTSSITGB3ITGA2B | |
| SCHEMBL1645920 | 0.81 | SMN1; SMN2 (0.45) | SMN1; SMN2CTSKCTSSITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090170878-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS | NOVARTIS AG (CH) | 2009-07-02 | — | — | US | disclosed |
| EP-2046760-A1 | MACROCYCLIC LACTAMS | Novartis AG (CH) | 2009-04-15 | — | — | EP | disclosed |
| WO-2008009734-A1 | MACROCYCLIC LACTAMS | NOVARTIS AG (CH) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170878-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS | BACE2, BACE1, APP | SMN1; SMN2 1039/4885CTSK 57/4885NFKB1 339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.